Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgment of Support

This activity is supported by an educational grant from Arcutis Biotherapeutics, Inc.

Novel Interventions Targeting Itch Pathways in Skin Disease

Release Date: August 5, 2021
Expiration Date: August 5, 2022

Activity Overview

Chronic skin conditions with pruritis have a significant effect on quality of life with sleep disturbances and functional impairment resulting in poorer performance at work or school. Although topical therapies are the mainstay of therapy, gaps in treatment remain with varying degrees of efficacy in reducing itch and patient satisfaction with the agent’s vehicle, as well as substantial safety concerns, particularly with long-term use of topical corticoid steroids. New topical therapies are emerging that specifically target the pathophysiological mechanisms involved in itch associated with skin diseases and offer an improved safety profile.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the virtual symposium at the Canadian Dermatological Society annual meeting held June 26, 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with chronic skin conditions associated with itch and putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Arcutis Biotherapeutics, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward dermatologists, family practice clinicians, and other health care professionals who treat patients with chronic skin conditions.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe the pathophysiology of itch
  • Analyze safety and efficacy data for emerging topical therapies that target itch pathways in skin diseases
  • Identify characteristics of vehicles used in topical agents for skin diseases that impact patient preferences for therapy

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

Program Chair

David N. Adam, MD, FRCPC, DABD
David N. Adam, MD, FRCPC, DABD
Medical Director, Baywood Dermatology
Lead Investigator, CCA Medical Research
Assistant Professor, University of Toronto
Active Staff, St. Michael’s Hospital
President, Dermatology Association of Ontario
Toronto, Canada

Disclosures: Grant/Research Support: AbbVie, Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Coherus BioSciences, Dermira, Dermavant Sciences, Eli Lilly, Incyte Corporation, Janssen Pharmaceutical, Leo Pharma, Pfizer, Regeneron Pharmaceuticals; Consultant: AbbVie, Actelion Pharmaceuticals, Amgen, Celgene Corporation, Eli Lilly and Company, Galderma, Janssen Pharmaceutical, Leo Pharma, Merck & Co, Novartis Pharmaceuticals Corporation, Pfizer, Sanofi Genzyme, Sun Pharmaceuticals, Valeant Pharmaceuticals.


Mark G. Lebwohl, MD
Mark G. Lebwohl, MD
Dean, Clinical Therapeutics
Professor, Dermatology
Icahn School of Medicine
Mount Sinai
New York, NY

Disclosures: Grant/Research Support: AbbVie, Amgen, Arcutis Biotherapeutics, Avotres Therapeutics, Boehringer Ingelheim, Dermavant Sciences, Eli Lilly and Company, Incyte, Janssen Research & Development, Ortho Dermatologics, Regeneron Pharmaceuticals, UCB; Consultant: Aditum Bio, Almirall, AltruBio, AnaptysBio, Arcutis Biotherapeutics, Aristea Therapeutics, Arrive Technologies, Avotres Therapeutics, BiomX, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Corona Pharmaceuticals, Dermavant Sciences, Dr. Reddy’s Laboratories, Evelo Biosciences, Evommune, Facilitation for International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Helsinn Therapeutics, Hexim Pharmaceuticals, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Seanergy, Verrica Pharmaceuticals.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By